A Multicenter, Randomized, Open‐Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of clinical pharmacology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270010377501PMID 20852004PMCID PMC3190583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD)

  2010cited by this paper
• Dosing in Children

  2010cited by this paper
• A Global, Evidence-Based Consensus on the Definition of Gastroesophageal Reflux Disease in the Pediatric Population

  2009cited by this paper
• Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)

  2009cited by this paper
• Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients.

  2009cited by this paper
• PROTONIX®(pantoprazole sodium)Delayed-Release Tablets PROTONIX ®(pantoprazole sodium)For Delayed-Release Oral Suspension

  2009cited by this paper
• Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.

  2008cited by this paper
• Mechanism-based concepts of size and maturity in pharmacokinetics.

  2008cited by this paper
• Single‐Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents

  2008cited by this paper
• Knowledge, Attitudes and Practice Styles of North American Pediatricians Regarding Gastroesophageal Reflux Disease

  2007cited by this paper
• Drug metabolism in the paediatric population and in the elderly.

  2007cited by this paper
• Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.

  2007cited by this paper
• Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.

  2006cited by this paper
• Multicenter, Randomized, Double-Blind Study Comparing 20 and 40 mg of Pantoprazole for Symptom Relief in Adolescents (12 to 16 Years of Age) with Gastroesophageal Reflux Disease (GERD)

  2006cited by this paper
• Multicenter, Randomized, Double-Blind Study Comparing 10, 20 and 40 mg Pantoprazole in Children (5-11 Years) With Symptomatic Gastroesophageal Reflux Disease

  2006cited by this paper
• Pharmacogenetics and pharmacogenomics.

  2005influential reference
• Review article: similarities and differences among delayed‐release proton‐pump inhibitor formulations

  2005cited by this paper
• Pharmacokinetics of Proton Pump Inhibitors in Children

  2005cited by this paper
• Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children.

  2005influential reference
• gastro-oesophageal reflux disease : the health economic implications

  2005cited by this paper
• Prevention of erosive oesophagitis relapse with pantoprazole

  2004cited by this paper
• Developmental Expression of Human Hepatic CYP2C9 and CYP2C19

  2004cited by this paper
• Pharmacogenomics of proton pump inhibitors.

  2004influential reference
• Proton Pump Inhibitors in Pediatrics: Relevant Pharmacokinetics and Pharmacodynamics

  2003cited by this paper
• Developmental pharmacology--drug disposition, action, and therapy in infants and children.

  2003cited by this paper
• Pharmacogenetics and pharmacogenomics.

  2001cited by this paper
• Pharmacokinetics of orally administered omeprazole in children

  2000cited by this paper
• Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole--a preliminary study.

  1997cited by this paper
• Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S‐mephenytoin 4′‐hydroxylation phenotype and genotype *

  1997cited by this paper
• Pharmacokinetics of pantoprazole in man.

  1996cited by this paper
• Pharmacokinetics of pantoprazole in man.

  1996cited by this paper
• Effect of repeated oral administration of BY 1023/SK&F 96022 – a new substituted benzimidazole derivative – on pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man

  1990cited by this paper

• Safety of intravenous pantoprazole sodium in paediatric patients aged 1 year to <2 years: a real-world retrospective cohort study in the USA

  2026cites this paper
• Safety of Intravenous Pantoprazole Sodium in Pediatric Patients Aged 1 Month to < 1 Year: A Real-World Retrospective Cohort Study

  2023cites this paper
• Pharmacological treatment of gastro-oesophageal reflux in children.

  2023cites this paper
• Current Status of Pharmacokinetic Research in Children: A Systematic Review of Clinical Trial Records.

  2022cites this paper
• Utility of the 13C‐pantoprazole breath test as a CYP2C19 phenotyping probe for children

  2022cites this paper
• Metabolomic profiling of extraesophageal reflux disease in children

  2021cites this paper
• Gastroesophageal Reflux

  2021cites this paper
• Neonatal Pharmacogenetics

  2019cites this paper
• Gastroesophageal re fl ux disease : exaggerations , evidence and clinical practice ☆

  2019cites this paper
• A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents

  2018cites this paper
• Pantoprazole pharmacokinetics in obese children: normalized to lean or ideal weight?

  2018cites this paper
• Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures

  2018cites this paper
• Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

  2018cites this paper
• Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition

  2018cites this paper
• Reply.

  2018cites this paper
• A randomized, crossover pharmacodynamic study of immediate‐release omeprazole/sodium bicarbonate and delayed‐release lansoprazole in healthy adult volunteers

  2016cites this paper
• Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy

  2016cites this paper
• Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review

  2015cites this paper
• Management of paediatric GERD

  2014cites this paper
• Effect of proton pump inhibition on acid, weakly acid and weakly alkaline gastro-esophageal reflux in children

  2013cites this paper
• H+/K+-ATPase inhibitors: a patent review

  2013cites this paper
• Proton Pump Inhibitors in Pediatrics

  2013cites this paper
• Gastroesophageal Reflux Disease in Children and Adolescents

  2012cites this paper
• Developmental pharmacogenomics

  2011cites this paper
• Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children

  2011cites this paper
• Review of pantoprazole in pediatrics

  2011cites this paper
• Drug Evaluation Review of pantoprazole in pediatrics

  2011cites this paper
• Development of biomarkers to optimize pediatric patient management: what makes children different?

  2011cites this paper
• Questionable international pediatric studies with Swiss participation

  year unknowncites this paper